Type your tag names separated by a space and hit enter

Dermatitis Herpetiformis

Dermatitis Herpetiformis is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --



  • Dermatitis herpetiformis (DH) presents as a chronic, relapsing, polymorphous, intensely pruritic, erythematous papulovesicular eruption with symmetrical distribution primarily involving extensor skin surfaces of the elbows, knees, buttocks, back, and scalp.
  • DH is an autoimmune disease associated with gluten sensitivity with genetic, environmental, and immunologic influences.
  • DH is distinguished from other bullous diseases by characteristic histologic and immunologic findings, as well as associated gluten-sensitive enteropathy (GSE).
  • System(s) affected: skin
  • Synonym(s): Duhring disease, Duhring-Brocq disease


  • Occurs most frequently in those of Northern European origin
  • Rare in persons of Asian or African American origin
  • Predominant age: most common in 4th and 5th decades but may present at any age
  • Childhood DH is rare in most countries, although an Italian study showed 27% of patients were age of <10 years and 36% age of <20 years.
  • Predominant gender: adults: male > female (1.5:1 in the United States, 2:1 worldwide); children: female > male

1/100,000 persons per year in the United States

11/100,000 persons in the U.S. population; as high as 39/100,000 persons worldwide

Etiology and Pathophysiology

  • Evidence suggests that epidermal transglutaminase (eTG) 3, a keratinocyte enzyme involved in cell envelope formation and maintenance, is the autoantigen in DH.
  • eTG is highly homologous with tissue transglutaminase (tTG), which is the antigenic target in celiac disease and GSE.
  • The initiating event for DH is presumed to be the interaction of wheat peptides with tTGs, which results in the formation of an autoantigen with high affinity for particular class II major histocompatibility complex (MHC) molecules.
  • Presentation of the autoantigen leads to activation of T-cells and the humoral immune system.
  • IgA antibodies against tTG cross-react with eTG and result in IgA-eTG immune complexes that are deposited in the papillary dermis. Subsequent activation of complement and recruitment of neutrophils to the area result in inflammation and microabscesses.
  • Skin eruption may be delayed up to 5 to 6 weeks after exposure to gluten.
  • Gluten applied directly to the skin does not result in the eruption, whereas gluten taken by mouth or rectum does. This implies necessary processing by the GI system.
  • Thought to be immune complex–mediated disease

  • High association with human leukocyte antigen DQ2 (95%), with remaining patients being positive for DQ8, DR4, or DR3
  • Strong association with combination of alleles DQA1*0501 and DQB1*0201/0202, DRB1*03 and DRB1*05/07, or DQA1*0301 and DQB1*0302

Risk Factors

  • GSE: >90% of those with DH will have GSE, which may be asymptomatic.
  • Family history of DH or celiac disease

General Prevention

Gluten-free diet (GFD) results in improvement of DH and reduces dependence on medical therapy. GFD also may reduce the risk of lymphomas associated with DH.

Commonly Associated Conditions

  • Hypothyroidism is the most common condition associated with DH.
  • GSE, gluten ataxia
  • Gastric atrophy, hypochlorhydria, pernicious anemia
  • GI lymphoma, non-Hodgkin lymphoma
  • Hyperthyroidism, thyroid nodules, thyroid cancer
  • IgA nephropathy
  • Autoimmune disorders, including systemic lupus erythematosus, dermatomyositis, Sjögren syndrome, rheumatoid arthritis, sarcoidosis, Raynaud phenomenon, insulin-dependent diabetes mellitus, myasthenia gravis, Addison disease, vitiligo, alopecia areata, primary biliary cirrhosis, and psoriasis

-- To view the remaining sections of this topic, please or purchase a subscription --


Stephens, Mark B., et al., editors. "Dermatitis Herpetiformis." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/117579/all/Dermatitis_Herpetiformis.
Dermatitis Herpetiformis. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/117579/all/Dermatitis_Herpetiformis. Accessed April 19, 2019.
Dermatitis Herpetiformis. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/117579/all/Dermatitis_Herpetiformis
Dermatitis Herpetiformis [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 April 19]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/117579/all/Dermatitis_Herpetiformis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Dermatitis Herpetiformis ID - 117579 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/117579/all/Dermatitis_Herpetiformis PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -